Synthesis and Biological Evaluation of Novel Alkyl Amine Substituted Icariside II Derivatives as Potential Anticancer Agents

Network pharmacology analysis of Icariside II against bladder cancer

As a global health threat, bladder cancer (BC) is a common urological disease characterized by a high risk of progression and recurrence. Icariside II (ICA-II), a flavonol glycoside, exhibits antitumor ability in various tumors. However, there is no systematic study exploring the pharmacological mechanism of ICA-II in BC. We used public databases to obtain potential targets of ICA-II and related genes in BC. Bioinformatics analysis and molecular docking were used to identify potential targets and signaling pathways. Then, MTT, cell cycle assays and western blot (WB) were used to validate the predicted pathways in bladder cell lines, and in situ bladder cancer models were also established to verify the effect of ICA-II. Our research demonstrated that these ICA-II hub genes were related to the cell cycle. Then, our molecular docking analysis confirmed the interaction between ICA-II and CCNB1. In addition, our in vitro experiment demonstrated that ICA-II restrained the proliferation of BC cells mainly by blocking the cell cycle. WB also verified that ICA-II decreased the expression levels of CCNB1. In situ BC models showed that ICA-II had no hepatotoxicity or nephrotoxicity and could suppress the growth of in situ BC. In summary, during this study, we found that ICA-II had low toxicity in the kidney and liver. Network pharmacology was used, and both cell and animal experiments verified that ICA-II has a good therapeutic effect on bladder cancer, which may inhibit the proliferation and progression of bladder cancer by blocking the cell cycle of BC cells.

Synthesis, evaluation of anti-breast cancer activity in vitro of ICS II derivatives and summary of the structure-activity relationship

A series of Icariside II (ICS II) derivatives were synthesized, and their structure-activity relationships (SARs) were studied in this paper. The in vitro antitumor activities towards human breast cancer cell lines (MCF-7) were evaluated by Cell Counting Kit-8 (CCK-8 kit). Preliminary results showed that, compared with ICS II, most of the derivatives displayed good micromole level activities. Among the series of derivatives, the S27, which totally acetylated hydroxyl of ICS II, possessed highest cytotoxicity, with IC₅₀ values of 0.70 ± 0.08 μM. Furthermore, compound S27 showed better selectivity than ICS II for cancer cells over normal cells. Our findings indicate that compound S27 may be a promising anticancer lead candidate drug.

Anticancer activity of Mannich bases: a review of recent literature

This report summarizes the latest published data on the antiproliferative action and cytotoxic activity of Mannich bases, a structurally heterogeneous category of chemical entities that includes compounds which are synthesized via the grafting of an aminomethyl function onto diverse substrates by means of the Mannich reaction. The present overview of the topic is an update to the information assembled in a previously published review that covered the literature up to 2014.

Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma

The prenylated flavonoid icaritin (ICT) is currently undergoing phase 3 clinical trial for the treatment of advanced hepatocellular carcinoma (HCC), based on a solid array of preclinical and clinical data. The antitumor activity originates from the capacity of the drug to modulate several signaling effectors in cancer cells, mainly the estrogen receptor splice variant ERα36, the transcription factors STAT3 and NFκB, and the chemokine receptor CXCR4. Recent studies have implicated additional components, including different microRNAs, the generation of reactive oxygen species and the targeting of sphingosine kinase-1. ICT also engages the RAGE-HMGB1 signaling route and modulates the apoptosis/autophagy crosstalk to promote its anticancer activity. In addition, ICT exerts profound changes on the tumor microenvironment to favor an immune-response. Collectively, these multiple biochemical and cellular characteristics confer to ICT a robust activity profile which can be exploited to treat HCC, as well as other cancers, including glioblastoma and onco-hematological diseases such as chronic myeloid leukemia. This review provides an update of the pharmacological properties of ICT and its metabolic characteristics. It also addresses the design of derivatives, including both natural products and synthetic molecules, such as SNG1153 also in clinical trial. The prenylated flavonoid ICT deserves attention as a multifunctional natural product potentially useful to improve the treatment of advanced hepatocellular carcinoma.

Validating interfacial behaviour of surface-active ionic liquids (SAILs) with computational study integrated with biocidal and cytotoxic assessment

Surface-active ionic liquids (SAILs) belonging to the series of N-alkylmethylimidazolium halides [C₈mimX] (X = Br, Cl, and BF₄) and [C_nmimBr] (n = 10, 12, 14, and 16) were employed to understand the influence of hydrophobicity of alkyl chain length and the chaotropicity of counter-ions of SAILs on the micellization, antimicrobial action and cytotoxicity properties. The micellization phenomenon of SAILs in an aqueous environment was examined employing tensiometry and steady-state fluorescence spectrophotometry. The corresponding interfacial parameters viz., critical micelle concentration (CMC), effectiveness (γ_CMC), surface pressure (П_CMC), maximum surface excess concentration (Г_max), and the minimum area engaged per molecule (A_min) at the air-water interface were evaluated at 303.15 K. These experimental findings were monitored and geometrically optimized theoretically using Gaussian software to highlight the recent advances in this field of theoretical calculations for putative structure. The simulation descriptors correlated the micellization behavior as a function of hydrophobicity which may contribute to obtaining awareness on their ecological behavior and fate. In addition, the biological screening of all the examined SAILs was undertaken with a combined experimental and theoretical (optimized) method against bacteria and fungus. Results revealed that SAILs with the alkyl chain-length greater than C₈- act as a fair antimicrobial agent against the selected microbial strain which is attributed to the enhanced degree of SAILs hydrophobicity. The cytotoxicity of these imidazolium-based SAILs was also assessed on the cervical human cell line (HeLa) using the MTT cell viability assay and the data thus obtained were subjected to statistical analysis.